Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37,911 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT).
Galarza Fortuna GM, Grass D, Maughan BL, Jain RK, Dechet C, Beck J, Schuetz E, Sanchez A, O'Neil B, Poch M, Li R, Lloyd S, Tward J, Phunrab T, Hawks JL, Swami U, Boucher KM, Agarwal N, Gupta S. Galarza Fortuna GM, et al. Among authors: li r. J Immunother Cancer. 2025 Mar 18;13(3):e010572. doi: 10.1136/jitc-2024-010572. J Immunother Cancer. 2025. PMID: 40102029 Free PMC article. Clinical Trial.
Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
Li R, Nocera L, Rose KM, Raggi D, Naidu S, Mercinelli C, Cigliola A, Tateo V, Patanè D, Grass GD, Gilbert SM, Sexton WJ, Bandini M, Moschini M, Briganti A, Montorsi F, Spiess PE, Necchi A. Li R, et al. Eur Urol Oncol. 2024 Jun;7(3):614-624. doi: 10.1016/j.euo.2023.12.008. Epub 2024 Jan 6. Eur Urol Oncol. 2024. PMID: 38184473
Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma.
Huelster HL, Gould B, Schiftan EA, Camperlengo L, Davaro F, Rose KM, Soupir AC, Jia S, Zheng T, Sexton WJ, Pow-Sang J, Spiess PE, Daniel Grass G, Wang L, Wang X, Vosoughi A, Necchi A, Meeks JJ, Faltas BM, Du P, Li R. Huelster HL, et al. Among authors: li r. Eur Urol. 2024 Mar;85(3):283-292. doi: 10.1016/j.eururo.2023.09.017. Epub 2023 Oct 4. Eur Urol. 2024. PMID: 37802683
Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.
Li R, Hensley PJ, Gupta S, Al-Ahmadie H, Babjuk M, Black PC, Brausi M, Bree KK, Fernández MI, Guo CC, Horowitz A, Lamm DL, Lerner SP, Lotan Y, Mariappan P, McConkey D, Mertens LS, Mir C, Ross JS, O'Donnell M, Palou J, Pohar K, Steinberg G, Soloway M, Spiess PE, Svatek RS, Tan WS, Taoka R, Buckley R, Kamat AM. Li R, et al. Eur Urol. 2024 Dec;86(6):516-527. doi: 10.1016/j.eururo.2024.08.001. Epub 2024 Aug 24. Eur Urol. 2024. PMID: 39183090 Review.
FGFR Inhibition in Urothelial Carcinoma.
Li R, Linscott J, Catto JWF, Daneshmand S, Faltas BM, Kamat AM, Meeks JJ, Necchi A, Pradere B, Ross JS, van der Heijden MS, van Rhijn BWG, Loriot Y. Li R, et al. Eur Urol. 2025 Feb;87(2):110-122. doi: 10.1016/j.eururo.2024.09.012. Epub 2024 Sep 30. Eur Urol. 2025. PMID: 39353825 Review.
Predicting Response to Intravesical Bacillus Calmette-Guérin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12-Center Cohort.
Lotan Y, Krishna V, Abuzeid WM, Launer B, Chang SS, Krishna V, Shingi S, Gordetsky JB, Gerald T, Woldu S, Shkolyar E, Hayne D, Redfern A, Spalding L, Stewart C, Eyzaguirre E, Imtiaz S, Narayan VM, Packiam VT, O'Donnell MA, Li R, Baekelandt L, Joniau S, Zuiverloon T, Fernandez MI, Schultz M, Hensley PJ, Allison D, Taylor JA, Hamza A, Kamat A, Nimgaonkar V, Sonawane S, Miller DL, Watson D, Vrabac D, Joshi A, Shah JB, Williams SB. Lotan Y, et al. Among authors: li r. J Urol. 2025 Feb;213(2):192-204. doi: 10.1097/JU.0000000000004278. Epub 2024 Oct 9. J Urol. 2025. PMID: 39383345
Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract.
Moussa MJ, Tabet GC, Siefker-Radtke AO, Xiao L, Wilson NR, Gao J, Logothetis CJ, Grivas P, Lee B, Shah AY, Msaouel P, Li R, Clemente LC, Zhao J, Tannir NM, Kamat AM, Hansel DE, Guo CC, Campbell MT, Alhalabi O. Moussa MJ, et al. Among authors: li r. Cancer Med. 2025 Jan;14(2):e70594. doi: 10.1002/cam4.70594. Cancer Med. 2025. PMID: 39831734 Free PMC article.
The role of neoadjuvant systemic therapy for high grade upper tract urothelial carcinoma: Results from the upper tract collaborative network (UCAN).
Carpinito GP, Gerald T, Hensley PJ, Martin AJ, Pallauf M, Pham J, Li R, Potretzke AM, Spiess PE, Singla N, Raman JD, Coleman J, Matin SF, Margulis V. Carpinito GP, et al. Among authors: li r. Urol Oncol. 2025 Jun;43(6):390.e1-390.e11. doi: 10.1016/j.urolonc.2024.11.025. Epub 2024 Dec 24. Urol Oncol. 2025. PMID: 39721824
37,911 results
You have reached the last available page of results. Please see the User Guide for more information.